Premium Industrial News

China's Pharma Tier 2 CDMOs Seek to Attain Tier 1 Status

China's Pharma Tier 2 CDMOs Seek to Attain Tier 1 Status

pharmaceutical

Industry Segment: Pharmaceutical & Biotech | Word Count: 230 Words
Attachment: A

BEIJING--September 8, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--China's Tier 2 pharmaceutical contract development and manufacturing companies (CDMOs) have the opportunity to leap to Tier 1 status as more Pharmaceutical & Biotech companies in the West outsource their services, and as China sees the benefits of its Marketing Authorization Holder (MAH) pharmaceutical regulatory system. Tier 2 CDMOs have annual revenue of up to US$500 million, while Tier 1 CDMOs have revenue of more than $US500 million.

This Premium Article can be purchased individually or as part of a subscription

Subscribe Now!(All Fields Required)

Subscription Type:

  • Pay-Per-Article - $5.95
  • Annual Premium News Subscription - $365.00
Pricing Help?